OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients
- Sponsor
- Royal College of Surgeons, Ireland
- Study ID
- NCT07426848
- Status
- Recruiting
Conditions
- Brain Neoplasms
- Glioblastoma
- Primary Brain Tumour
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Standard Lifestyle Management Literature — OTHERProvision of written educational materials addressing symptom management, fatigue, activity pacing, and lifestyle strategies. Participants continue routine oncology care without structured occupational therapy group sessions.
- OT SMILE Occupational Therapy Group Programme — BEHAVIORALA structured six-week group-based occupational therapy programme delivered by registered occupational therapists. Sessions include fatigue management strategies, goal setting, activity pacing, cognitive strategies, relaxation techniques, exercise guidance, nutrition education, peer support, and strategies to support long-term self-management. Each session lasts approximately 90 minutes and is delivered weekly.
Study Details
People diagnosed with primary brain tumours often experience significant symptoms such as fatigue, cognitive changes, anxiety, and reduced ability to carry out everyday activities. These symptoms may be related to the tumour itself or to ongoing systemic anti-cancer treatment. In Ireland, access to structured rehabilitation and symptom management programmes for this population is limited. The OT SMILE study is evaluating whether a structured occupational therapy-led group programme can improve quality of life and daily functioning in adults with primary brain tumours receiving active treatment. Participants attending Beaumont Hospital who meet eligibility criteria and provide informed consent will be randomly assigned (like flipping a coin) to one of two groups: A six-week occupational therapy group programme (OT SMILE), or Usual care, consisting of written lifestyle management information. The OT SMILE programme consists of six weekly 90-minute group sessions delivered by occupational therapists. Sessions focus on fatigue management, activity modification, cognitive strategies, relaxation techniques, goal setting, exercise, nutrition, and peer support. Participants in both groups will complete questionnaires before the programme begins and again after six weeks. These questionnaires measure quality of life, fatigue, and daily functioning. The main goal of the study is to determine whether the occupational therapy group programme improves health-related quality of life compared to usual care. The results may help inform supportive care services for people living with primary brain tumours.
Key Dates
- First listed
- Feb 23, 2026
- Start date
- Dec 18, 2025
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 96 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Active Comparator: Standard Lifestyle Management Literature (Control)Participants receive standard written lifestyle management information regarding symptom management and self-care strategies and continue usual oncology care. No structured group intervention is provided.
- Experimental: OT SMILE Occupational Therapy Group InterventionParticipants receive a structured six-week occupational therapy-led group intervention in addition to usual oncology care. The programme consists of six weekly 90-minute sessions delivered in small groups (6-8 participants per cohort).
Primary Outcome Measure
Change in Functional Assessment of Cancer Therapy - Brain (FACT-BR) Total Score [ Time Frame: Baseline and 6 weeks (end of intervention period) ]
Central Contacts
- Caoilfhionn O Donovan+35318093000
Find similar trials
Related Studies
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOAPHASE2 · Recruiting · Northwell Health · New York, New York
- Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed GlioblastomaPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)PHASE2 · Recruiting · Patrick Wen, MD · Boston, Massachusetts
- Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBMPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York